MedTrace Logo

A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer

NCT06237257 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-12-24

No results posted yet for this study

Summary

The Primary purpose of this study is to evaluate the safety of SHR-1316 plus concurrent chemoradiotherapy in participants with locally advanced cervical cancer.

The second purpose of this study is to evaluate the efficacy and PK traits; The exploratory study is to explore the biomarker 、immunogenicity and so on .

Conditions

  • Locally Advanced Cervical Cancer

Interventions

BIOLOGICAL

SHR-1316

SHR-1316（Adebrelimab Injection）

DRUG

Cisplatin Injection/Carboplatin Injection

Cisplatin Injection/Carboplatin Injection

RADIATION

External Beam Radiotherapy (EBRT)/Brachytherapy

External Beam Radiotherapy (EBRT)/Brachytherapy

DRUG

Paclitaxel Injection

Paclitaxel Injection.

Sponsors & Collaborators

  • Shanghai Shengdi Pharmaceutical Co., Ltd

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-20
Primary Completion
2024-12-31
Completion
2025-01-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06237257 on ClinicalTrials.gov